Financings in Brief: Boston Biomedica
This article was originally published in The Gray Sheet
Boston Biomedica: Files registration statement with the Securities and Exchange Commission for an initial public offering with a proposed aggregate value of $22.1 mil. The manufacturer of quality control products for in vitro diagnostics plans to use $3.6 mil. of proceeds from the offering to repay debt; $1 mil. will fund an expansion of the firm's West Bridgewater, Massachusetts facilities. Remaining proceeds will be used for "general corporate purposes, including working capital, as well as for potential acquisitions and alliances," the registration statement says. Oscar Gruss & Son Incorporated and Kaufman Bros., L.P. are underwriting....
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.